Navigation Links
Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers

mulative platelet and neutrophil toxicity and mild diarrhea. Grade 1 neuropathy was observed in three patients, and no neuropathy higher than grade 1 was observed in any patients, including four patients who have received a cumulative dose >900 mg/m2. Transient grade 3-4 neutrophil toxicity occurred in 32 percent of patients and platelet toxicity in 13 percent of patients. Hematologic toxicity was more frequent in the every-two- week schedule. In the every-four-week schedule, no dose-limiting toxicity has been observed with doses of picoplatin up to 180 mg/m2. Picoplatin was administered at doses up to 90 mg/m2 every two weeks and 180 mg/m2 every four weeks. Both the biweekly and monthly regimens are still being evaluated to define their respective maximum tolerated doses.

Phase 1 HRPC Trial Data

The Phase 1 component of the HRPC trial is being conducted in patients with metastatic disease who had not previously been treated with chemotherapy. Study participants received either docetaxel 60 mg/m2 every three weeks plus prednisone 5 mg twice daily plus picoplatin or docetaxel 75 mg/m2 every three weeks plus prednisone 5 mg twice daily plus picoplatin. Picoplatin was given to sequential cohorts of subjects at 60, 80, 100 and 120 mg/m2 with docetaxel 60 mg/m2 and at 100 and 120 mg/m2 with docetaxel 75 mg/m2.

To date, 26 patients have been treated; four patients have completed 10 cycles of therapy and 15 patients remain on treatment. Therapy has been well tolerated, with transient grade 3-4 neutropenia occurring in 46 percent of patients and grade 3-4 thrombocytopenia in 8 percent of patients. Dose- limiting toxicity (grade 4 neutropenia) has been observed at 120 mg/m2 when given with 60 mg/m2 docetaxel. Dose reduction for persistent hematologic toxicity has been infrequent for doses less than 120 mg/m2 picoplatin, and there has been no cumulative myelotoxicity. Dose escalation continues with picoplatin with docetaxel at 75 mg/m2.

Planned Pha
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:4/21/2015)... 2015 Amgen (NASDAQ: AMGN ) today ... Key results include: , Total revenues increased 11 ... million, with 12 percent product sales growth driven primarily ... EPOGEN ® (epoetin alfa), Sensipar ® (cinacalcet) ... exchange rates impacted total revenue and product sales growth ...
(Date:4/21/2015)... 2015  Inmark,s acquisition of Saf-T-Pak last week ... Training, specifically Division 6.2.  For over 25 years, ... programs focusing on IATA, ICAO, US DOT, Transport ... "We were particularly interested in Saf-T-Pak,s proprietary ... internet training programs," said David Oyler , ...
(Date:4/21/2015)... , April 21, 2015 The global dermatology ... CAGR of 8.2% from 2014 to 2019. ... hold larger shares in the global dermatology diagnostic ... devices market is mainly attributed to a wide range ... growing demand of dermatologists, and technological advancements made in ...
Breaking Medicine Technology:Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 2Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 3Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 4Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 5Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 6Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 7Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 8Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 9Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 10Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 11Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 12Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 13Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 14Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 15Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 16Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 17Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 18Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 19Inmark's Acquisition Of Saf-T-Pak Results In Expansion Of Its Dangerous Goods Training Portfolio 2Dermatology Diagnostic Devices Market by Product, by End-User - Global Forecast to 2019 2Dermatology Diagnostic Devices Market by Product, by End-User - Global Forecast to 2019 3
... MELVILLE, N.Y. , July 19 Nycomed US Inc. today ... Executive Officer. He assumes immediate responsibility for Nycomed US Inc., including manufacturing ... commercial operations for the three marketing and sales divisions Fougera, PharmaDerm and ... , ...
... announces that a new market research report is available in its catalogue: , ... Global Pharma-biotech Alliance Analysis , ... , , , ... deals struck from 2008 to present. This study covers deal structures by therapeutic area, stage ...
Cached Medicine Technology:Steve Andrzejewski Joins Nycomed US Inc. 2Reportlinker Adds Global Pharma-biotech Alliance Analysis 2
(Date:4/21/2015)... (PRWEB) April 21, 2015 The Alzheimer’s ... partnership with JustSayCheese.com, a Colorado business that turns personal ... According to Larry Barrett, Vice President of Sales for ... in the fact that many of us have personal ... dedicated to working hard to support the Association’s efforts. ...
(Date:4/21/2015)... 21, 2015 Grafika is pleased to ... Offset Impressions. , “We’re excited about the ... printing capabilities and knowledgeable team members,” according to Bernard ... us to offer an ever wider breadth of products ... and specialty services we already offer. It also ...
(Date:4/21/2015)... “ ZeroWire ” was featured on ... takes a look at the latest and coolest technology ... special reporter for NewsWatch and a technology expert, conducted ... a security system and lifestyle management hub. , According ... 2 million burglaries in 2010. It goes without saying ...
(Date:4/21/2015)... Dallas, Texas (PRWEB) April 21, 2015 ... Review, H1 2015” provides comparative analysis on ... strengthens R&D pipelines by identifying new targets ... products. Complete report with TOC is available ... report also reviews key players involved in ...
(Date:4/21/2015)... AvePoint, the established leader in ... a new enhancement to DocAve Policy Enforcer ... Management Activity API. This integration creates a new information ... action on all events that take place throughout their ... Activity API provides customers with greater transparency and insight ...
Breaking Medicine News(10 mins):Health News:A Leader in Home Security was Featured on NewsWatch Television 2Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:AvePoint Integrates Microsoft Office 365 Management Activity API into DocAve Policy Enforcer for Proactive SharePoint Monitoring 2Health News:AvePoint Integrates Microsoft Office 365 Management Activity API into DocAve Policy Enforcer for Proactive SharePoint Monitoring 3
... Using insect repellent in addition to insecticide treated bednets (ITNs) ... areas where mosquitoes feed in the early evening. , The ... at the London School of Hygiene & Tropical Medicine and ... at the Ministry of Health in La Paz, Bolivia, are ...
... Nov. 12 What does a,thirty-nine foot Airstream Land ... For more than 800 midlands, men last month, it ... for the disease. The Drive Against Prostate Cancer ... prostate cancer. Doctors Care and WIS-TV,sponsored The Drive in ...
... China Pharma,Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI) ... at 11:00 a.m. EST on Thursday,November, 15, 2007, to ... Joining Ms. Zhilin Li, President and CEO of China ... Company plans to release its,earnings earlier that same day. ...
... Nov. 12 SpaCapsule(R),( http://www.spacapsule.com ), the most advanced ... one sleek, space-age,machine, has retained one of Florida,s ... quickest de-stressing and relaxation experience on,the planet. ... machine that in a matter,of minutes can take ...
... Rose 12.8% to US$14.3 Million (RMB 107.7 ... Million) Compared to Third Quarter 2006, BEIJING, ... FFHL ), a manufacturer and distributor of,high-quality BOPET plastic film ... quarter and for the nine months,ended September 30, 2007 which ...
... Global Landmarks Mark First United Nations World Diabetes Day ... up in blue to mark the,first United Nations-observed World ... most iconic buildings and sites. The landmarks will,light up ... circle, the global,symbol for diabetes. The Empire State ...
Cached Medicine News:Health News:Repellents between dusk and bedtime make insecticide-treated bednets more effective 2Health News:UCI Medical Affiliates, Inc. Sponsors Doctors Care Record-breaking Drive Against Prostate Cancer 2Health News:China Pharma Holdings, Inc. Announces Conference Call to Discuss Third Quarter 2007 Results 2Health News:The Ultimate Stress Reliever, SpaCapsule(R), the Capsule that Takes You on a Rejuvenating Journey to the Spa, Retains TransMedia Group for Soothing PR 2Health News:Fuwei Films Announces Third Quarter 2007 Financial Results 2Health News:Fuwei Films Announces Third Quarter 2007 Financial Results 3Health News:Fuwei Films Announces Third Quarter 2007 Financial Results 4Health News:Fuwei Films Announces Third Quarter 2007 Financial Results 5Health News:Fuwei Films Announces Third Quarter 2007 Financial Results 6Health News:World Diabetes Day Lights Up the Skyline 2Health News:World Diabetes Day Lights Up the Skyline 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: